Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04041479 · ClinicalTrials.gov registry record · Phase 3
Biomarker-guided rTMS for Treatment Resistant Depression
A Phase 3 study of Major Depressive Disorder and Treatment-Resistant Depression, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 348
- Enrollment target
- 2
- Study locations
NCT04041479 is a Phase 3 study of Major Depressive Disorder and Treatment-Resistant Depression that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 348 participants, roughly in line with the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target. The trial reports 2 study locations across 2 states.
The verdict
NCT04041479, a Phase 3 study of Major Depressive Disorder and Treatment-Resistant Depression, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 348 participants
- Enrollment target
- 2
- Study locations
Study Summary
Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. The investigators are continuing to learn how to optimize outcomes from rTMS treatment. The purpose of this research project is to use brain network connectivity patterns as measured by resting state functional magnetic resonance imaging (fMRI) to confirm a way to optimize the use of rTMS to treat depression. In addition, the study aims to gain a better understanding of how rTMS influences brain networks.
Conditions Studied
Interventions
- DEVICE Repetitive Transcranial Magnetic Stimulation
Study Locations (2)
California
- Stanford University - Stanford
New York
- Weill Cornell Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2021-09-17 |
| Est. Completion | 2027-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04041479
The ClinicalTrials.gov registry entry for NCT04041479 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 348 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Repetitive Transcranial Magnetic Stimulation is the first listed.
NCT04041479 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New York.
Frequently Asked Questions
What is clinical trial NCT04041479 about?
NCT04041479 is a clinical study titled "Biomarker-guided rTMS for Treatment Resistant Depression". Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. The investigators are continuing to learn how to optimize outcomes from rTMS treatment. The purpose of this research project is to use brain network connectivity patterns as measured by resting state functional magnet...
What is the current status of trial NCT04041479?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 348 participants. The study started on 2021-09-17. Estimated completion is 2027-08.
What conditions does trial NCT04041479 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Treatment-Resistant Depression.
What interventions are being tested in trial NCT04041479?
The interventions under investigation include: Repetitive Transcranial Magnetic Stimulation (DEVICE).
Who is sponsoring clinical trial NCT04041479?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04041479 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
Study to Assess the Safety and Effectiveness of NMRA-335140-501
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
RECRUITING · Phase 3
-
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
RECRUITING · Phase 3
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.